Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Osteonecrosis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteonecrosis - Pipeline Review, H2 2016, provides an overview of the Osteonecrosis (Musculoskeletal Disorders) pipeline landscape. Osteonecrosis is bone death caused by poor blood supply to the area. It is most common in the hip and shoulder, but can affect other large joints such as knee, elbow, wrist and ankle. Osteonecrosis can be caused by disease, or a severe trauma, such as a break or dislocation, that affects the blood supply to the bone. There are no symptoms in the early stages. Symptomatic treatment is available. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteonecrosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteonecrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Osteonecrosis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteonecrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively.Osteonecrosis. Osteonecrosis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Osteonecrosis (Musculoskeletal Disorders). - The pipeline guide reviews pipeline therapeutics for Osteonecrosis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Osteonecrosis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Osteonecrosis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Osteonecrosis (Musculoskeletal Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Osteonecrosis (Musculoskeletal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Osteonecrosis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Osteonecrosis Overview 6 Therapeutics Development 7 Pipeline Products for Osteonecrosis - Overview 7 Osteonecrosis - Therapeutics under Development by Companies 8 Osteonecrosis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Osteonecrosis - Products under Development by Companies 12 Osteonecrosis - Companies Involved in Therapeutics Development 13 Bone Therapeutics SA 13 Enzo Biochem Inc 14 K-Stemcell Co Ltd 15 Osteonecrosis - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Drug Profiles 23 ALLOB - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 LWnt-3a - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 PREOB - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecule to Agonize LRP for Osteonecrosis Of Jaws - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology and Cardiovascular Disease - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Osteonecrosis - Dormant Projects 33 Osteonecrosis - Product Development Milestones 34 Featured News & Press Releases 34 Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial 34 Jun 08, 2016: Bone Therapeutics demonstrates superiority of PREOB in Phase IIB osteonecrosis study presented at EULAR 34 May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study 35 Dec 04, 2014: Bone Therapeutics Authorised to Enrol Patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB 36 Nov 07, 2013: Bone Therapeutics' pivotal phase III osteonecrosis trial with PREOB hits a new milestone 36 Jan 28, 2013: Bone Therapeutics Raises €1.6m In Grant Subsidies From SRIW And Sambrinvest For Autologous Bone Cell Therapy 37 Oct 15, 2012: Bone Therapeutics Receives Clearance For Pivotal Phase III Osteonecrosis Trial With Preob In Europe And Treats The First Patients In Study 37 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
Number of Products under Development for Osteonecrosis, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Comparative Analysis by Early Stage Development, H2 2016 11 Products under Development by Companies, H2 2016 12 Osteonecrosis - Pipeline by Bone Therapeutics SA, H2 2016 13 Osteonecrosis - Pipeline by Enzo Biochem Inc, H2 2016 14 Osteonecrosis - Pipeline by K-Stemcell Co Ltd, H2 2016 15 Assessment by Monotherapy Products, H2 2016 16 Number of Products by Stage and Target, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 22 Osteonecrosis - Dormant Projects, H2 2016 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.